Abstract
Brain metastases are common in patients with non–small-cell lung cancer (NSCLC). Because of associated poor prognosis and limited specific treatment options, there is a real need for the development of medical therapies and strategies for affected patients. Novel compounds for epidermal growth factor receptor–dependent and anaplastic lymphoma kinase–dependent lung cancer have demonstrated blood-brain barrier permeability and have led to important improvements in central nervous system outcomes. Studies of targeted therapies for oncogene-driven tumors and of immunotherapies in patients with brain metastases have shown promise and, allied with novel radiation techniques, are driving a rapid evolution in treatment and prognosis for NSCLC brain metastases.
Original language | English (US) |
---|---|
Pages (from-to) | 156-163 |
Number of pages | 8 |
Journal | ONCOLOGY (United States) |
Volume | 32 |
Issue number | 4 |
State | Published - 2018 |
ASJC Scopus subject areas
- Oncology
- Cancer Research